RATIONALE: The scopolamine-reversal model is enjoying a resurgence of interest in clinical studies as a reversible pharmacological model for Alzheimer's disease (AD). The cognitive impairment associated with scopolamine is similar to that in AD. The scopolamine model is not simply a cholinergic model, as it can be reversed by drugs that are noncholinergic cognition-enhancing agents. OBJECTIVES: The objective of the study was to determine relevance of computer-assisted operant-conditioning tasks in the scopolamine-reversal model in rats and monkeys. MATERIALS AND METHODS: Rats were evaluated for their acquisition of a spatial reference memory task in the Morris water maze. A separate cohort was proficient in performance of an automated delayed stimulus discrimination task (DSDT). Rhesus monkeys were proficient in the performance of an automated delayed matching-to-sample task (DMTS). RESULTS: The AD drug donepezil was evaluated for its ability to reverse the decrements in accuracy induced by scopolamine administration in all three tasks. In the DSDT and DMTS tasks, the effects of donepezil were delay (retention interval)-dependent, affecting primarily short delay trials. Donepezil produced significant but partial reversals of the scopolamine-induced impairment in task accuracies after 2 mg/kg in the water maze, after 1 mg/kg in the DSDT, and after 50 microg/kg in the DMTS task. CONCLUSIONS: The two operant-conditioning tasks (DSDT and DMTS) provided data most in keeping with those reported in clinical studies with these drugs. The model applied to nonhuman primates provides an excellent transitional model for new cognition-enhancing drugs before clinical trials.
RATIONALE: The scopolamine-reversal model is enjoying a resurgence of interest in clinical studies as a reversible pharmacological model for Alzheimer's disease (AD). The cognitive impairment associated with scopolamine is similar to that in AD. The scopolamine model is not simply a cholinergic model, as it can be reversed by drugs that are noncholinergic cognition-enhancing agents. OBJECTIVES: The objective of the study was to determine relevance of computer-assisted operant-conditioning tasks in the scopolamine-reversal model in rats and monkeys. MATERIALS AND METHODS:Rats were evaluated for their acquisition of a spatial reference memory task in the Morris water maze. A separate cohort was proficient in performance of an automated delayed stimulus discrimination task (DSDT). Rhesus monkeys were proficient in the performance of an automated delayed matching-to-sample task (DMTS). RESULTS: The AD drug donepezil was evaluated for its ability to reverse the decrements in accuracy induced by scopolamine administration in all three tasks. In the DSDT and DMTS tasks, the effects of donepezil were delay (retention interval)-dependent, affecting primarily short delay trials. Donepezil produced significant but partial reversals of the scopolamine-induced impairment in task accuracies after 2 mg/kg in the water maze, after 1 mg/kg in the DSDT, and after 50 microg/kg in the DMTS task. CONCLUSIONS: The two operant-conditioning tasks (DSDT and DMTS) provided data most in keeping with those reported in clinical studies with these drugs. The model applied to nonhuman primates provides an excellent transitional model for new cognition-enhancing drugs before clinical trials.
Authors: John N Bain; Mark A Prendergast; Alvin V Terry; Stephen P Arneric; Mark A Smith; Jerry J Buccafusco Journal: Psychopharmacology (Berl) Date: 2003-05-27 Impact factor: 4.530
Authors: Amit Reches; Naama Levy-Cooperman; Ilan Laufer; Revital Shani-Hershkovitch; Keren Ziv; Dani Kerem; Noga Gal; Yaki Stern; Guy Cukierman; Myroslava K Romach; Edward M Sellers; Amir B Geva Journal: J Mol Neurosci Date: 2014-02-18 Impact factor: 3.444
Authors: Scott J Webster; Christina A Wilson; Chih-Hung Lee; Eric G Mohler; Alvin V Terry; Jerry J Buccafusco Journal: Br J Pharmacol Date: 2011-10 Impact factor: 8.739
Authors: Ruifeng Liu; Jonathan Crawford; Patrick M Callahan; Alvin V Terry; Christos Constantinidis; David T Blake Journal: Curr Biol Date: 2017-08-17 Impact factor: 10.834
Authors: Jan Laczó; Hana Markova; Veronika Lobellova; Ivana Gazova; Martina Parizkova; Jiri Cerman; Tereza Nekovarova; Karel Vales; Sylva Klovrzova; John Harrison; Manfred Windisch; Kamil Vlcek; Jan Svoboda; Jakub Hort; Ales Stuchlik Journal: Psychopharmacology (Berl) Date: 2016-11-24 Impact factor: 4.530
Authors: Robert A Lenz; Jeffrey D Baker; Charles Locke; Lynne E Rueter; Eric G Mohler; Keith Wesnes; Walid Abi-Saab; Mario D Saltarelli Journal: Psychopharmacology (Berl) Date: 2011-09-08 Impact factor: 4.530